LDL-cholesterol/apolipoprotein B ratio is a good predictor of LDL phenotype B in type 2 diabetes

被引:43
作者
Wägner, AM
Jorba, O
Rigla, M
Alonso, E
Ordóñez-Llanos, J
Pérez, A
机构
[1] Univ Autonoma Barcelona, Hosp Sant Pau, Endocrinol & Nutr Dept, E-08025 Barcelona, Spain
[2] Univ Autonoma Barcelona, Hosp Sant Pau, Dept Biochem, E-08025 Barcelona, Spain
[3] Univ Autonoma Barcelona, Hosp Sant Pau, Biochem & Mol Biol Dept, E-08025 Barcelona, Spain
关键词
LDL size; LDL phenotype B; LDL-cholesterol/apolipoprotein B ratio; type; 2; diabetes;
D O I
10.1007/s005920200037
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
LDL phenotype B is a component of diabetic dyslipidaemia, but its diagnosis is cumbersome. Our aim was to find easily available markers of phenotype B in a group of type 2 diabetic subjects. We studied 123 type 2 diabetic patients (67.5% male, aged 59.3 +/- 10.1 years, mean HbA1c 7.4%). Clinical features and fasting total cholesterol, triglyceride, HDL-cholesterol, LDL-cholesterol (LDLc, using Friedewald's equation and an alternative formula), apolipoprotein B (apoB), lipoprotein (a) and LDL particle size (on gradient polyacrylamide gel electrophoresis) were assessed. Patients with phenotypes A (predominant LDL size greater than or equal to25.5 nm) and B (<25.5 nm) were compared, and regression analysis was performed to find the best markers of LDL particle. Cut-off points were obtained and evaluated as predictors of phenotype B (kappa index). Patients with phenotype B (36%) showed higher total cholesterol, triglyceride and apolipoprotein B, and lower HDL cholesterol and LDLc/apoB ratio. Triglyceride was the best predictor of LDL particle size (r=-0.632, p<0.01), but an LDLc/apoB ratio below 1.297 mmol/g detected phenotype B best (sensitivity 65.9%, specificity 92.4%, kappa=0.611). Although triglyceride concentration is the best predictor of LDL size in type 2 diabetes, LDLcholesterol/apolipoproteinB ratio is the best tool to detect phenotype B.
引用
收藏
页码:215 / 220
页数:6
相关论文
共 29 条
[1]   ABNORMAL CHOLESTEROL DISTRIBUTION AMONG LIPOPROTEIN FRACTIONS IN NORMOLIPIDEMIC PATIENTS WITH MILD NIDDM [J].
ABATE, N ;
VEGA, GL ;
GARG, A ;
GRUNDY, SM .
ATHEROSCLEROSIS, 1995, 118 (01) :111-122
[2]  
Altman DG, 1991, PRACTICAL STAT MED R, P396
[3]  
[Anonymous], 1999, Diabet Med, V16, P716
[4]  
AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917
[5]   Optimization of glycemic control by insulin therapy decreases the proportion of small dense LDL particles in diabetic patients [J].
Caixas, A ;
OrdonezLlanos, J ;
deLeiva, A ;
Payes, A ;
Homs, R ;
Perez, A .
DIABETES, 1997, 46 (07) :1207-1213
[6]   LDL PARTICLE-SIZE DISTRIBUTION - RESULTS FROM THE FRAMINGHAM OFFSPRING STUDY [J].
CAMPOS, H ;
BLIJLEVENS, E ;
MCNAMARA, JR ;
ORDOVAS, JM ;
POSNER, BM ;
WILSON, PWF ;
CASTELLI, WP ;
SCHAEFER, EJ .
ARTERIOSCLEROSIS AND THROMBOSIS, 1992, 12 (12) :1410-1419
[7]  
FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
[8]  
Furuya D, 2000, CLIN CHEM, V46, P1202
[9]   ROLE OF PLASMA TRIGLYCERIDE IN THE REGULATION OF PLASMA LOW-DENSITY-LIPOPROTEIN (LDL) SUBFRACTIONS - RELATIVE CONTRIBUTION OF SMALL, DENSE LDL TO CORONARY HEART-DISEASE RISK [J].
GRIFFIN, BA ;
FREEMAN, DJ ;
TAIT, GW ;
THOMSON, J ;
CASLAKE, MJ ;
PACKARD, CJ ;
SHEPHERD, J .
ATHEROSCLEROSIS, 1994, 106 (02) :241-253
[10]   Inter-relationships between small, dense low-density lipoprotein (LDL), plasma triacylglycerol and LDL apoprotein B in an atherogenic lipoprotein phenotype in free-living subjects [J].
Griffin, BA ;
Minihane, AM ;
Furlonger, N ;
Chapman, C ;
Murphy, M ;
Williams, D ;
Wright, JJ ;
Williams, CM .
CLINICAL SCIENCE, 1999, 97 (03) :269-276